Consistent with the in vitro data, both CML and EGFR-driven lung cancer patients carrying the polymorphism experienced inferior responses to treatment with tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.